Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains antigens derived from selected influenza A and B virus strains. When injected, these antigens are processed by the immune system, stimulating B‑cells to produce strain‑specific antibodies and activating T‑cells. The resulting immune response creates immunological memory, enabling the body to recognise and neutralise the same virus strains if encountered later.

The prescribed dose of Influvac is determined by the treating healthcare professional. Typically, a single dose of the injectable solution is given intramuscularly or subcutaneously each influenza season. The exact volume and administration schedule are set by the prescriber based on age, health status, and local vaccination guidelines.

Safety data for Influvac in pregnant or lactating individuals are limited, but influenza vaccination is generally recommended when the benefits of preventing flu outweigh potential risks. Healthcare providers should assess each case individually and discuss the decision with the patient, considering current guidelines and the mother’s health condition.

To place an order, submit an enquiry on the Influvac product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with any required import documentation.

Influvac is an inactivated, split‑virus vaccine that targets the same influenza A and B strains as many other seasonal flu vaccines. Compared with live‑attenuated nasal sprays, Influvac is administered by injection and is suitable for a broader range of age groups, including immunocompromised patients. Its safety and efficacy profile aligns with EU‑approved standards for seasonal influenza immunisation.

Influvac must be stored refrigerated at 2 °C to 8 °C. The vials should be kept in their original packaging, protected from light, and must not be frozen or shaken. Prior to administration, allow the product to reach room temperature if required, and inspect for any discoloration or particulate matter before use.

Influvac is supplied as an injectable solution for intramuscular or subcutaneous injection. A qualified healthcare professional selects the appropriate injection site—typically the deltoid muscle for intramuscular delivery or the upper arm for subcutaneous administration—and follows aseptic technique. The dose is administered as a single injection per vaccination season.

Serious adverse events are rare but may include anaphylaxis, a severe allergic reaction that requires immediate medical attention, and Guillain‑Barré syndrome, a neurological disorder that can develop within weeks after vaccination. High fever, seizures, or severe local reactions are also possible. Patients should be observed after injection and instructed to seek care promptly if serious symptoms arise.

Influvac should be avoided in individuals with a known severe allergy to any component of the vaccine or who have experienced a previous severe reaction to an influenza vaccine. Persons with a history of severe egg allergy should be evaluated carefully, as trace egg protein may be present. Those with acute febrile illness should postpone vaccination until recovery.